The discovery emerged from a systematic examination of how the GBP family behaves during HSV-1 infection. When the researchers depleted GBP7 from infected cells, viral replication dropped markedly, an outcome opposite to what would be expected from a conventional antiviral factor. The effect was not subtle. Knockdown of GBP7 produced significant antiviral consequences, and the team traced this activity to the enzyme’s catalytic core: when its GTPase function was disabled, the proviral effect vanished. In other words, it is not merely the presence of GBP7 but its enzymatic activity that matters, a detail that would later prove central to both the mechanism and the therapeutic strategy that grew out of the work.

To determine whether the phenomenon extended beyond the culture dish, the investigators turned to mice engineered to lack the GBP7 gene. When these GBP7-deficient animals were infected with HSV-1, they fared substantially better than their wild-type counterparts. Survival rates climbed, and the clinical symptoms of infection were milder across the course of the disease. The in vivo data confirmed that the proviral role observed in cells translates into a meaningful determinant of disease severity in a living host. For a gene induced by interferon, the canonical signal of antiviral mobilization, to instead enhance viral fitness in vivo represents an unexpected twist in the biology of this protein family.

The search for a mechanism led the team to the translational apparatus of the host cell itself. Using immunoprecipitation followed by mass spectrometry, a technique that captures a bait protein along with everything physically bound to it and identifies the passengers, the researchers found that GBP7 associates with eukaryotic translation elongation factor 1 alpha 1, or eEF1A1. This factor is one of the most abundant and essential components of the protein synthesis machinery, responsible for delivering aminoacylated transfer RNAs to the ribosome during each elongation cycle. Binding between GBP7 and eEF1A1 was subsequently validated with direct affinity assays, establishing that the interaction is physical and specific rather than an artifact of the screening method.

What makes the partnership consequential is its effect on the enzymology of translation. eEF1A1 is itself a GTPase: each cycle of tRNA delivery requires the factor to bind GTP, and the energy of GTP hydrolysis drives the conformational changes that allow the factor to release the tRNA into the ribosomal acceptor site and dissociate for another round. The study found that GBP7 uses its own GTPase activity to assist eEF1A1 in this hydrolysis step, effectively speeding up the elongation factor’s catalytic cycle. With eEF1A1 working faster, the overall rate of protein translation in the cell rises. For a virus like HSV-1, which commandeers the host translational machinery to mass-produce its own proteins, a turbocharged elongation factor is a direct growth advantage.

The consequences for the virus follow logically from the biochemistry. With GBP7 present and active, eEF1A1 accelerates protein synthesis, viral proteins accumulate more rapidly, and viral replication proceeds at a higher rate, deepening the infection. When GBP7 is removed, or when its GTPase activity is lost, the boost disappears and the virus replicates more poorly. This mechanistic chain, from GTPase-assisted GTP hydrolysis to enhanced elongation to increased viral output, provides a coherent explanation for every observation in the study, from the cell culture knockdown experiments to the improved survival of GBP7-deficient mice. It also reframes GBP7 as part of a growing appreciation that interferon-stimulated genes can cut both ways, sometimes serving pathogens that have learned to exploit the host’s defensive mobilization.

Identifying a host factor that a virus exploits naturally raises the question of whether that dependency can be turned against the pathogen. Because the proviral effect requires GBP7’s catalytic activity, the enzyme’s GTP-binding and hydrolysis site presents an obvious drug target. The team pursued this avenue through high-throughput virtual screening, computationally docking large libraries of candidate molecules against the protein in search of compounds predicted to occupy and disable its active site. Among the hits that emerged was S-adenosylhomocysteine, or SAH, a well-known metabolite that is produced naturally in cellular methylation reactions as the byproduct of S-adenosylmethionine-dependent methyltransferase activity.

Experimental testing confirmed the computational prediction. SAH bound and inhibited GBP7, and in cells infected with HSV-1 the compound displayed potent antiviral activity, suppressing replication in a manner consistent with the loss of GBP7’s proviral function. Notably, the authors report that SAH showed broad-spectrum potential, suggesting that the GBP7-eEF1A1 axis may be exploited by viruses beyond herpes simplex virus 1. If that holds up in further studies, a strategy aimed at dampening this host pathway could offer a template for antivirals that are harder for viruses to escape, since the target is a host protein rather than a viral one. Host-targeted antivirals generally impose a higher genetic barrier to resistance, because the pathogen cannot simply mutate the drugged protein.

The findings also carry implications for how the GBP family is understood. GBPs have been studied most intensively in the context of immunity to intracellular bacteria and parasites, where several members direct autophagy, inflammasome activation and direct antimicrobial attack. GBP7 had remained comparatively obscure, and the new work assigns it a defined and surprising role: an interferon-induced GTPase that potentiates translation elongation through a direct physical partnership with eEF1A1. That a family member deployed during antiviral signaling would instead facilitate a viral infection underscores how incomplete the functional annotation of interferon-stimulated genes remains, and it raises the possibility that other GBPs or related GTPases may harbor similarly counterintuitive activities in different infection contexts.

For the field of antiviral research, the study offers both a mechanism and a starting point. The GBP7-eEF1A1 axis is now a defined node at which viral replication can be throttled, and SAH provides a chemical lead whose activity against HSV-1 can be optimized and whose spectrum can be mapped. At the same time, many questions remain open, including precisely how GBP7’s GTPase cycle is coupled to eEF1A1’s hydrolysis step, whether the interaction is regulated during the interferon response, and how inhibiting the axis in patients might affect normal cellular protein synthesis, given eEF1A1’s essential housekeeping role. What the work establishes firmly is that the boundary between host defense and viral exploitation is thinner than the textbook account of the GBPs suggests, and that a protein summoned to the front lines of the immune response can end up serving the enemy’s supply chain.

Subject of Research: The role of the GTPase GBP7 and the translation factor eEF1A1 in herpes simplex virus 1 replication and host-targeted antiviral therapy

Article Title: GTPase GBP7 promotes HSV-1 infection by interacting with and activating eEF1A1 to accelerate the protein translation process

Article References: Wang, J., Man, L., Rong, B., Lu, K., Cheng, L., He, J., Li, H., Su, H., Lin, X., Li, R., Zou, M., Yang, C., & Liu, S. (2026). GTPase GBP7 promotes HSV-1 infection by interacting with and activating eEF1A1 to accelerate the protein translation process. PLOS Pathogens, 22(10), e1014652. https://doi.org/10.1371/journal.ppat.1014652

Image Credits: AI Generated

DOI: 10.1371/journal.ppat.1014652

Keywords: GBP7, guanylate-binding proteins, HSV-1, herpes simplex virus, eEF1A1, protein translation, GTPase, interferon, host-targeted antivirals, S-adenosylhomocysteine, viral replication, PLOS Pathogens

The review, authored by a team led by researchers at Chinese PLA General Hospital in Beijing together with colleagues at the Shenzhen Institutes of Advanced Technology and Tianjin University, lays out in systematic detail the barriers that have frustrated glioblastoma immunotherapy. The tumor is extraordinarily heterogeneous, both across patients and within a single lesion, with spatially distinct subclones carrying different antigenic profiles. Its immune infiltrate is dominated not by cytotoxic lymphocytes but by immunosuppressive myeloid cells, including tumor-associated macrophages and microglia, which actively dampen T-cell responses. Lymphocyte infiltration is restricted, antigens are unstable and evolve under treatment pressure, and the blood–brain barrier limits delivery of both antibodies and cells. Corticosteroid exposure, nearly universal in these patients, further suppresses immunity, and standard therapies themselves remodel the immune environment in ways that are difficult to model.

Conventional preclinical tools capture only fragments of this complexity. Established glioblastoma cell lines, propagated for years in serum, drift genetically and immunologically from the tumors they originally came from. Xenografts in immunocompromised mice cannot interrogate an intact immune system. Genetically engineered mouse models, while immunocompetent, do not reproduce the human tumor’s molecular and cellular idiosyncrasies. The result is a persistent translation gap: interventions that look promising in the laboratory repeatedly fail in the clinic because no model faithfully predicted how a specific patient’s tumor and immune system would interact with the drug.

Patient-derived glioblastoma organoids, or GBOs, have emerged as a partial answer. These three-dimensional cultures are generated directly from resected surgical specimens and, crucially, retain key histological, genetic, and phenotypic features of the parental tumor, including its cellular diversity and much of its microenvironmental architecture. Because they can be established rapidly and expanded in vitro, they allow functional therapeutic testing on a timescale that could theoretically inform clinical decisions. The review emphasizes that this combination of fidelity and tractability is what distinguishes organoids from earlier patient-derived systems such as neurospheres and spheroids.

The technical evolution of the platform is a central theme. Early organoid protocols produced relatively uniform tumor epithelial cultures, but newer approaches preserve immune cells within the organoid, generating what the authors describe as tumor-immune organoids that model the interaction between malignant cells and infiltrating myeloid and lymphoid populations. Co-culture strategies now allow researchers to introduce autologous or allogeneic immune cells, T cells engineered with chimeric antigen receptors, or immune checkpoint inhibitors, and to measure killing, cytokine release, and immune exhaustion in a controlled three-dimensional setting that approximates the tumor’s physical structure.

Applications span the full immuno-oncology repertoire. The review details how GBOs are being used to model responses to checkpoint blockade, to evaluate cellular therapies such as CAR-T and CAR-NK cells, to screen myeloid-targeting agents that reprogram immunosuppressive macrophages, and to test therapeutic vaccines. Multi-omic readouts—single-cell RNA sequencing, spatial transcriptomics, and epigenetic profiling applied to organoids before and after treatment—allow researchers to connect a treatment response to specific cell states and signaling pathways within the same patient’s tumor. Artificial intelligence-assisted image analysis is increasingly used to quantify spatial relationships between tumor cells and immune populations, extracting predictive features that would be invisible to manual assessment.

Particular emphasis is placed on oncolytic virotherapy, and specifically on engineered herpes simplex virus type 1 vectors. Oncolytic viruses are designed to infect and lyse tumor cells selectively while simultaneously provoking an antitumor immune response, and herpes-based vectors have the advantages of a large genetic payload capacity, well-characterized engineering tools, and clinical precedent. The review argues that GBOs are uniquely suited to interrogate the critical steps of viral therapy in human tissue: viral entry into tumor cells, the efficiency of intracellular replication, the spatial pattern of spread through the three-dimensional tumor mass, and the innate antiviral restriction mechanisms—such as type I interferon signaling—that can determine whether an oncolytic approach succeeds or fails in a given patient.

Beyond single-agent testing, organoids enable rational combination design. Immunogenic cell death triggered by viral lysis can release tumor antigens and danger signals, potentially converting a cold, lymphocyte-poor tumor into one that responds to checkpoint blockade. GBOs allow researchers to test such combinations—virus plus PD-1 inhibition, virus plus myeloid reprogramming, virus plus adoptive cell transfer—in the same specimen, identifying synergies and antagonisms before committing to a clinical regimen. The authors also outline staged, clinically integrated workflows in which organoid testing could be embedded within surgical and oncological care, with results returned in time to influence adjuvant treatment decisions.

The review is notably candid about limitations. Immune cells within organoids undergo attrition over time in culture, so experiments must be performed within narrow windows before the immune compartment degrades. Microenvironmental fidelity is incomplete: the blood–brain barrier, systemic immune circuits, and corticosteroid effects cannot be fully reproduced in a dish. Resource requirements are substantial, demanding rapid processing of fresh tissue, specialized culture infrastructure, and multidisciplinary expertise. Most importantly, the platform has not yet been validated prospectively—no trial has demonstrated that organoid-based testing reliably predicts clinical response. The authors call for small exploratory trials designed specifically to establish this predictive validity.

Even with those caveats, the trajectory is clear. As protocols standardize, as immune preservation improves, and as AI-driven analysis matures, patient-derived glioblastoma organoids are positioned to become a bridge between genomic profiling and functional precision medicine in neuro-oncology. For a disease in which nearly every immunotherapeutic advance has stalled at the bedside, the ability to rehearse a treatment against a living replica of a patient’s own tumor—complete with its immune defenders and saboteurs—represents one of the most consequential opportunities in the field. Whether that opportunity translates into longer survival will depend on the prospective studies the review’s authors say must now follow.

Subject of Research: Patient-derived glioblastoma organoids as models for tumor-immune interactions and oncolytic virotherapy in immuno-oncology

Article Title: Patient-derived glioblastoma organoids in immuno-oncology: tumor-immune modeling, oncolytic virotherapy, and translational opportunities

Article References: Liu, J., Liu, T., Wang, Y., Guo, B., Gao, Z., Su, S., Liu, Y., Xu, A., Li, W., Yang, Z., Li, M., Li, S., Wang, H., Lv, W., Xu, F., & Zhang, J. (2026). Patient-derived glioblastoma organoids in immuno-oncology: tumor-immune modeling, oncolytic virotherapy, and translational opportunities. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04530-9

Image Credits: AI Generated

DOI: 10.1007/s00262-026-04530-9

Keywords: glioblastoma, patient-derived organoids, immuno-oncology, oncolytic virotherapy, herpes simplex virus, tumor microenvironment, checkpoint blockade, CAR-T cells, myeloid cells, precision oncology, blood-brain barrier, immunotherapy

Herpetic whitlow results when herpes simplex virus, most commonly herpes simplex virus type 1, inoculates the skin of a digit through a break in the cutaneous barrier. The virus travels to sensory nerve endings, establishes infection in the distal phalanx, and produces one or more intensely painful vesicles that may coalesce into a larger blister resembling a bacterial felon or paronychia. The infection classically affects the thumb and index finger, though any digit may be involved. In children, autoinoculation from thumb-sucking or finger-sucking during oral herpetic infections is the dominant route of acquisition, while in adults the disease has historically been an occupational hazard among dentists, dental hygienists, and other health care workers exposed to oral secretions before the widespread adoption of gloves.

The historical record captured in the review begins with early observations that established whitlow as a nosocomial threat. Among the foundational works cited is a 1959 Lancet study by Stern and colleagues describing herpetic whitlow as a form of cross-infection in hospitals, a report that helped define the condition’s public health significance at a time when its viral etiology was still being separated from pyogenic infections of the hand. By the end of the twentieth century, larger clinical series such as the 1990 analysis by Gill and colleagues of herpes simplex virus infection of the hand, published in the Journal of the American Academy of Dermatology, had clarified the spectrum of disease in adults and children alike, documenting incubation periods, recurrence patterns, and the substantial morbidity that recurrent infection imposes on patients.

The technical groundwork for the present synthesis rests on several strands of evidence. Case reports of pediatric whitlow, exemplified by the 2001 European Journal of Pediatrics report by Szinnai and colleagues describing multiple herpetic whitlow lesions in a four-year-old girl, illustrate how extensive the lesions can become in young children and how easily the presentation can be mistaken for more common blistering disorders. Occupational case series, including the 2012 report by Browning and McCarthy in the Journal of Esthetic and Restorative Dentistry documenting herpes simplex virus as an occupational hazard among dental practitioners, reinforce the role of exposure routes in shaping who develops the disease. On the therapeutic side, the pharmacological understanding of nucleoside analogs such as acyclovir and its relatives has matured considerably, as summarized in the 2022 PharmGKB review by Maillard and colleagues of the acyclovir and ganciclovir metabolic pathway, which maps how these prodrugs are converted by viral and cellular thymidine kinases into active triphosphate forms that selectively inhibit viral DNA polymerase.

By pooling published case material, the Weill Cornell-led team sought to define the epidemiological and clinical profile of herpetic whitlow with more precision than any single case report could provide. The review’s design reflects a growing appreciation in dermatology that rare or underrecognized conditions accumulate meaningful evidence only when scattered reports are aggregated and analyzed together. The researchers coordinated the project across four institutions, with Vijayvargiya responsible for data collection, Vijayvargiya and Zhou performing the analysis and drafting, Singal contributing to conception, design, and revision, and Lipner overseeing the work and providing final approval. The authors declared no competing interests and reported no external funding for the study, and the paper was accepted on 1 September 2026 and published on 12 September 2026 in volume 318 of the journal.

The clinical importance of distinguishing herpetic whitlow from bacterial infections of the hand cannot be overstated. Misdiagnosis as a bacterial felon or paronychia has historically led to incision and drainage, a surgical intervention that is not only unnecessary for viral infection but potentially harmful, because breaching the skin can introduce secondary bacterial infection or delay appropriate antiviral therapy. Recognizing the characteristic morphology of whitlow, grouped vesicles on an erythematous base with a predilection for the distal phalanx, along with a history of prior oral or genital herpes lesions, exposure to oral secretions, or recent trauma to the digit, allows clinicians to avoid inappropriate surgery and initiate antiviral treatment promptly. Diagnostic confirmation, when needed, can be achieved through viral culture, polymerase chain reaction testing, or Tzanck smear, though the classic presentation in most cases permits clinical diagnosis.

Therapy for herpetic whitlow rests on antiviral agents, principally acyclovir, valacyclovir, and famciclovir, which shorten the duration of viral shedding and accelerate healing when initiated early in the course of infection. The pharmacogenetic pathway described by Maillard and colleagues explains both the selectivity and the limitations of these drugs: acyclovir is preferentially phosphorylated by virus-encoded thymidine kinase, concentrating active drug in infected cells, but resistance can emerge in immunocompromised patients through loss or alteration of the viral kinase, in which case drugs with alternative mechanisms, such as foscarnet, may be required. For immunocompetent patients, most episodes resolve spontaneously within two to four weeks, though recurrent disease can be frequent, painful, and disruptive, particularly for health care workers whose livelihoods depend on unimpaired hand function.

Prevention strategies highlighted across the reviewed literature emphasize simple but effective measures. The dramatic decline in occupational whitlow among dental professionals after routine gloving became standard practice stands as one of the clearest demonstrations that barrier precautions control transmission of herpes simplex virus in clinical settings. In households, parents and caregivers with active oral herpes lesions can reduce transmission to children by avoiding kissing children on or near the mouth, not sharing utensils and towels, and discouraging thumb-sucking in children with active herpetic gingivostomatitis. People with recurrent whitlow can reduce autoinoculation risk by avoiding contact between their lesions and other body sites, particularly the eyes, where herpes infection can threaten vision.

The consolidated picture that emerges from this review serves a dual purpose. For clinicians, it provides an evidence-based reference point for recognizing a condition that, despite its distinctive appearance, continues to be misdiagnosed in emergency departments, pediatric clinics, and dermatology practices. For researchers, it identifies gaps in the literature, including the relative scarcity of prospective studies and randomized treatment trials in both children and adults, since most of the evidence base remains built on individual case reports and small series. As antiviral pharmacology advances and awareness of occupational and household transmission routes deepens, syntheses of the kind now published by the Weill Cornell, Rutgers, and Columbia collaboration help ensure that the accumulated clinical wisdom of six decades of case reporting is not lost but translated into better diagnosis, more judicious treatment, and fewer preventable infections of the hand.

Subject of Research: Herpetic whitlow: a systematic review of published herpes simplex virus infection cases of the fingers

Article Title: Review of published herpetic whitlow cases

Article References: Vijayvargiya, N., Singal, A., Zhou, M. H., & Lipner, S. R. (2026). Review of published herpetic whitlow cases. Archives of Dermatological Research, 318(1), Article 412. https://doi.org/10.1007/s00403-026-04923-x

Image Credits: AI Generated

DOI: 10.1007/s00403-026-04923-x

Keywords: herpetic whitlow, herpes simplex virus, dermatology, acyclovir, occupational infection, pediatric herpes, antiviral therapy, nail and hand infection, case report review, viral infection, dental health workers, autoinoculation